Integrin Inhibitors & TGF-β: Anti-Fibrotic Strategy

Introduction

TGF-β (Transforming Growth Factor-β) is one of the most important cytokines promoting fibrosis. However, since TGF-β is also essential for immune regulation and wound healing, direct inhibition can cause severe side effects.

An approach to solve this problem focuses on inhibiting tissue-specific TGF-β activation via integrins. Integrins function as "gatekeepers" for TGF-β, converting latent TGF-β to its active form.

Mechanism: Integrins and TGF-β Activation

Structure of Latent TGF-β

TGF-β is secreted as a latent complex bound to LAP (Latency-Associated Peptide). This complex is stored by binding to LTBP (Latent TGF-β Binding Protein) in the extracellular matrix (ECM).

Integrin-Mediated Activation

Specific integrins bind to the RGD sequence within LAP and apply mechanical force to release and activate TGF-β.

Key Integrin Isoforms

Integrin	Primary Expression	TGF-β Activation	Disease Relevance
αvβ6	Epithelial cells (lung, liver, kidney)	High	IPF, MASH
αvβ1	Fibroblasts	High	Pan-fibrosis
αvβ8	Immune cells, neurons	Moderate	Autoimmune, neurological
αvβ3	Vascular endothelium, osteoclasts	Low	Angiogenesis, bone remodeling

Integrin Inhibitors in Development

Key Pipeline

Compound	Target	Developer	Stage	Indication	Status
Bexotegrast (PLN-74809)	αvβ6/αvβ1	Pliant Therapeutics	Phase 2b/3	IPF	Discontinued (2025)
IDL-2965	αvβ1/αvβ3/αvβ6	Indalo Therapeutics	Phase 1/2	IPF, MASH	Ongoing
GSK3008348	αvβ6	GSK	Phase 1	IPF	Completed (safety only)
BG00011 (STX-100)	αvβ6 antibody	Biogen	Phase 2	IPF	Completed

Lessons from Bexotegrast

Pliant Therapeutics' Bexotegrast was the most advanced integrin inhibitor, but the Phase 2b/3 BEACON-IPF trial was discontinued in 2025.

Reasons for Discontinuation:

• Independent data safety monitoring board noted imbalance in IPF-related adverse events compared to placebo
• Specific adverse event details not publicly disclosed

Possible Challenges:

1. Selectivity issues: Simultaneous inhibition of αvβ6 and αvβ1 may have caused unexpected effects
2. Dose optimization: Balance between degree of inhibition and safety
3. Patient selection: Lack of proper stratification using appropriate biomarkers

Future of Integrin Targeting Strategies

Next-Generation Approaches

1. Single isoform-selective inhibition: Selectively inhibit only αvβ6 or only αvβ1
2. Inhaled formulations: Reduce systemic exposure through local pulmonary delivery (for IPF)
3. PROTACs: Induced degradation of integrin proteins

Importance of Biomarkers

Appropriate patient selection is essential for success of integrin inhibition therapy:

• αvβ6 expression levels: Evaluation in BAL fluid or biopsy specimens
• Imaging biomarkers: Visualization using integrin-targeted PET tracers
• Blood biomarkers: Active TGF-β levels, ECM metabolites

Evaluation in Preclinical Models

Recommended Models

Model	Advantage	Evaluation Endpoints
Bleomycin lung fibrosis	Confirmed αvβ6 upregulation	Lung function, collagen, αvβ6 IHC
CDAA MASH	αvβ1 expression in hepatic stellate cells	Liver fibrosis score, Sirius Red
UUO renal fibrosis	Rapid fibrosis induction	Integrin expression, α-SMA

Key Evaluation Points

1. Target occupancy: Confirm degree of integrin inhibition after dosing
2. Active TGF-β measurement: Tissue and blood levels
3. Downstream signaling: Western blot or IHC for pSmad2/3

Summary

Integrin inhibition is a promising approach to "smart" TGF-β suppression, but as the discontinuation of Bexotegrast demonstrates, balancing isoform selectivity and safety is critical. Next-generation integrin inhibitors, when more selective and administered to appropriate patients, have the potential to become breakthroughs in fibrosis treatment.

Accurately evaluating integrin expression at the preclinical stage and confirming target engagement is key to clinical success.

---

References

1. Henderson NC, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617-1624.
2. Munger JS, et al. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319-328.
3. Pliant Therapeutics Press Release (2025): BEACON-IPF Trial Discontinuation.
4. Reed NI, et al. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med. 2015;7(288):288ra79.